Free Trial

RAPT Therapeutics (RAPT) Stock Forecast & Price Target

$3.29
-0.14 (-4.08%)
(As of 07/19/2024 ET)

RAPT Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 13 Wall Street analysts who have issued ratings for RAPT Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 13 analysts, 9 have given a hold rating, and 4 have given a buy rating for RAPT.

Consensus Price Target

$24.67
649.75% Upside
High Forecast$41.00
Average Forecast$24.67
Low Forecast$4.00

According to the 13 analysts' twelve-month price targets for RAPT Therapeutics, the average price target is $24.67. The highest price target for RAPT is $41.00, while the lowest price target for RAPT is $4.00. The average price target represents a forecasted upside of 649.75% from the current price of $3.29.

TypeCurrent Forecast
7/22/23 to 7/21/24
1 Month Ago
6/22/23 to 6/21/24
3 Months Ago
4/23/23 to 4/22/24
1 Year Ago
7/22/22 to 7/22/23
Consensus Rating
Hold
Hold
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
6 Buy rating(s)
9 Buy rating(s)
Hold
9 Hold rating(s)
9 Hold rating(s)
6 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$24.67$24.67$25.67$40.60
Forecasted Upside649.75% Upside71.45% Upside65.52% Upside99.60% Upside
Get RAPT Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter.

RAPT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RAPT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

RAPT Therapeutics Stock vs. The Competition

TypeRAPT TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.31
2.72
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside649.75% Upside3,282.89% Upside10.04% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/14/2024Wolfe Research
3 of 5 stars
 Reiterated RatingOutperform ➝ Peer Perform
5/10/2024Guggenheim
3 of 5 stars
Y. Suneja
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
5/10/2024Barclays
2 of 5 stars
 DowngradeOverweight ➝ Equal Weight$13.00 ➝ $4.00-14.16%
4/10/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Selvaraju
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral
3/27/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$15.00 ➝ $13.00+51.52%
2/22/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$61.00 ➝ $10.00-1.77%
2/21/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Smith
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
2/21/2024SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$42.00 ➝ $10.00+45.56%
2/20/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Agrawal
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral
2/16/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
9/14/2023Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$34.00+77.64%
8/14/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$28.00 ➝ $31.00+29.33%
8/8/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$40.00+77.15%
3/15/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$27.00 ➝ $23.00+20.73%
1/4/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$55.00 ➝ $48.00+157.93%
9/21/2022Capital One Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Z. Jallah
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$48.00+98.76%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 05:26 AM ET.

RAPT Forecast - Frequently Asked Questions

What is RAPT Therapeutics' forecast for 2024?

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for RAPT Therapeutics is $24.67, with a high forecast of $41.00 and a low forecast of $4.00.

Should I buy or sell RAPT Therapeutics stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for RAPT Therapeutics in the last twelve months. There are currently 9 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" RAPT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RAPT, but not buy additional shares or sell existing shares.

Does RAPT Therapeutics's stock price have much upside?

According to analysts, RAPT Therapeutics's stock has a predicted upside of 71.45% based on their 12-month stock forecasts.

Has RAPT Therapeutics been downgraded by Wall Street analysts recently?

Over the previous 90 days, RAPT Therapeutics's stock had 2 downgrades by analysts.

What analysts cover RAPT Therapeutics?

RAPT Therapeutics has been rated by research analysts at Barclays, Guggenheim, and Wolfe Research in the past 90 days.

Do Wall Street analysts like RAPT Therapeutics more than its competitors?

Analysts like RAPT Therapeutics less than other "medical" companies. The consensus rating for RAPT Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how RAPT compares to other companies.


This page (NASDAQ:RAPT) was last updated on 7/21/2024 by MarketBeat.com Staff

From Our Partners